These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 11907488)

  • 21. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
    Frye RF; Branch RA
    Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype.
    Jan MW; ZumBrunnen TL; Kazmi YR; VanDenBerg CM; Desai HD; Weidler DJ; Flockhart DA
    Drug Metabol Drug Interact; 2002; 19(1):1-11. PubMed ID: 12222750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
    Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
    Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omeprazole weakly inhibits CYP1A2 activity in man.
    Rost KL; Fuhr U; Thomsen T; Zaigler M; Brockmöller J; Bohnemeier H; Roots I
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):567-74. PubMed ID: 10584979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
    von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
    Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
    Spigset O; Hägg S; Söderström E; Dahlqvist R
    Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
    Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
    Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
    Wang Y; Zhang H; Meng L; Wang M; Yuan H; Ou N; Zhang H; Li Z; Shi R
    Eur J Clin Pharmacol; 2010 Jun; 66(6):563-9. PubMed ID: 20414645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fluvoxamine-caffeine interaction study.
    Jeppesen U; Loft S; Poulsen HE; Brśen K
    Pharmacogenetics; 1996 Jun; 6(3):213-22. PubMed ID: 8807660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro.
    Rasmussen BB; Nielsen TL; Brøsen K
    Pharmacol Toxicol; 1998 Dec; 83(6):240-5. PubMed ID: 9868741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19.
    Rost KL; Roots I
    Hepatology; 1996 Jun; 23(6):1491-7. PubMed ID: 8675169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.
    Christensen M; Andersson K; Dalén P; Mirghani RA; Muirhead GJ; Nordmark A; Tybring G; Wahlberg A; Yaşar U; Bertilsson L
    Clin Pharmacol Ther; 2003 Jun; 73(6):517-28. PubMed ID: 12811361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.
    von Bahr C; Ursing C; Yasui N; Tybring G; Bertilsson L; Röjdmark S
    Eur J Clin Pharmacol; 2000 May; 56(2):123-7. PubMed ID: 10877005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin.
    Zhou Q; Yamamoto I; Fukuda T; Ohno M; Sumida A; Azuma J
    Eur J Clin Pharmacol; 1999 Mar; 55(1):43-7. PubMed ID: 10206083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction.
    Haas CE; Brazeau D; Cloen D; Booker BM; Frerichs V; Zaranek C; Frye RF; Kufel T
    Eur J Clin Pharmacol; 2005 Sep; 61(8):583-93. PubMed ID: 16041547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans.
    Becquemont L; Ragueneau I; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 1997 Jun; 61(6):619-27. PubMed ID: 9209244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.